Objective:

To understand the use of intrapericardial triamcinolone in children with recurrent idiopathic pericardial effusion.

Approach:

Key Findings:

• Nine pediatric patients underwent intrapericardial triamcinolone administration.
• Cytological, microbiological, and inflammatory marker testing of pericardial fluid showed elevated protein and LDH levels; all cultures and PCR tests were negative.
• Median age at treatment was 21.5 months, with a range from 2 months to 16 years.
• Duration of clinical stability post-triamcinolone varied, with a median time of 22.5 days between initial effusion drainage and treatment.

Interpretation:

Limitations:

• Retrospective design may introduce bias.
• Small sample size limits generalizability.
• Lack of standardized echocardiographic measurement criteria.

Conclusion:

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.